Open access
Open access
Powered by Google Translator Translator

Gastroenterology

Cohort Study | Alcohol abstinence improves prognosis across all stages of portal hypertension in alcohol-related cirrhosis

24 Jan, 2023 | 14:14h | UTC

Alcohol abstinence improves prognosis across all stages of portal hypertension in alcohol-related cirrhosis – Clinical Gastroenterology and Hepatology

News Release: Scientists provide evidence of the positive effects of alcohol abstinence in advanced liver cirrhosis – University of Viena / News Medical

 


Cohort Study | Prevalence of colorectal neoplasia 10 or more years after a negative screening colonoscopy in 120 000 repeated screening colonoscopies

23 Jan, 2023 | 13:36h | UTC

Prevalence of Colorectal Neoplasia 10 or More Years After a Negative Screening Colonoscopy in 120 000 Repeated Screening Colonoscopies – JAMA Internal Medicine

Commentaries:

Prevalence of Colorectal Cancers Low 10 Years Following Negative Screening Test – HCP Live

Risk for Advanced Neoplasm Low 10+ Years After Negative Colonoscopy – HealthDay

 

Commentary on Twitter

 


M-A | Dietary interventions for the treatment of inflammatory bowel diseases

20 Jan, 2023 | 14:30h | UTC

Dietary interventions for the treatment of inflammatory bowel diseases: an updated systematic review and meta-analysis – Clinical Gastroenterology and Hepatology

 

Commentary on Twitter

Under a Creative Commons (CC BY-NC-ND 4.0) License

 


Cross-sectional study | Non-heavy alcohol use associated with liver fibrosis and ‘nonalcoholic’ steatohepatitis

20 Jan, 2023 | 14:29h | UTC

Non-heavy alcohol use associates with liver fibrosis and ‘nonalcoholic’ steatohepatitis in the Framingham Heart Study – Clinical Gastroenterology and Hepatology (link to abstract – $ for full-text)

Commentary: Study finds non-heavy alcohol use associated with liver fibrosis – Boston University School of Medicine

 


ACC Guidelines Update | Diagnosis and management of celiac disease

18 Jan, 2023 | 14:40h | UTC

American College of Gastroenterology Guidelines Update: Diagnosis and Management of Celiac Disease – The American Journal of Gastroenterology

Commentaries: 

ACG updates, reaffirms guidelines on evaluation, management of patients with celiac disease – ACP Internist

ACG Updates Clinical Guidance on Diagnosing Celiac Disease – HCP Live

 


ACG Clinical Guideline | Diagnosis and management of gastrointestinal subepithelial lesions

18 Jan, 2023 | 14:39h | UTC

ACG Clinical Guideline: Diagnosis and Management of Gastrointestinal Subepithelial Lesions – The American Journal of Gastroenterology

Related: AGA Clinical Practice Update on Management of Subepithelial Lesions Encountered During Routine Endoscopy: Expert Review – Clinical Gastroenterology and Hepatology

 


Cohort Study | Proton pump inhibitors are unlikely to be major teratogens during pregnancy

18 Jan, 2023 | 14:14h | UTC

Association Between Proton Pump Inhibitor Use During Early Pregnancy and Risk of Congenital Malformations – JAMA Network Open

 

Commentary on Twitter

 


RCT | Reduced adenoma miss rate with 9-minute vs. 6-minute withdrawal times for screening colonoscopy

18 Jan, 2023 | 14:13h | UTC

Reduced Adenoma Miss Rate With 9-Minute vs 6-Minute Withdrawal Times for Screening Colonoscopy: A Multicenter Randomized Tandem Trial – The American Journal of Gastroenterology

Commentary: Longer withdrawal time reduces miss rates in screening colonoscopy – MDedge

 

Commentary on Twitter

 


AGA clinical practice update on diagnosis and management of acute hepatic porphyrias

17 Jan, 2023 | 13:19h | UTC

AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review – Gastroenterology

 


RCT | Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn’s disease on combination therapy

17 Jan, 2023 | 13:10h | UTC

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn’s disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial – The Lancet Gastroenterology & Hepatology

Invited commentary: Treatment withdrawal in Crohn’s disease: slowly becoming clearer – The Lancet Gastroenterology & Hepatology (free registration required)

 

Commentary on Twitter

 


Review | Liver intensive care for the general intensivist

17 Jan, 2023 | 12:59h | UTC

Liver intensive care for the general intensivist – Anaesthesia

 


Development and validation of a prognostic nomogram for older patients with acute-on-chronic liver diseases

15 Jan, 2023 | 19:46h | UTC

A novel prognostic nomogram for older patients with acute-on-chronic liver diseases (AoCLD): a nationwide, multicentre, prospective cohort study – Age and Ageing

See also: dynamic nomogram

 


Cohort Study | Antibiotic exposure linked to increased risk of inflammatory bowel disease

13 Jan, 2023 | 13:25h | UTC

Antibiotic use as a risk factor for inflammatory bowel disease across the ages: a population-based cohort study – Gut

News Release: Frequent use of antibiotics may heighten inflammatory bowel disease risk in over 40s – BMJ Newsroom

Commentaries: 

Antibiotics may increase risk of inflammatory bowel disease, study finds – CIDRAP

Antibiotic Exposure Positively Linked to IBD Development – HealthDay

 

Commentary on Twitter

 


Review | The pathogenesis and therapeutic strategies of heat stroke-induced liver injury

13 Jan, 2023 | 13:07h | UTC

The pathogenesis and therapeutic strategies of heat stroke-induced liver injury – Critical Care

 


RCT | Second-line levofloxacin-based quadruple therapy vs. bismuth-based quadruple therapy for Helicobacter pylori eradication

12 Jan, 2023 | 13:06h | UTC

Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


M-A | Blood endotoxin levels as biomarker of non-alcoholic fatty liver disease

12 Jan, 2023 | 12:57h | UTC

Blood endotoxin levels as biomarker of non-alcoholic fatty liver disease: a systematic review and meta-analysis – Clinical Gastroenterology and Hepatology

 


Review | Early diagnosis and prevention of infections in cirrhosis

12 Jan, 2023 | 12:47h | UTC

Early Diagnosis and Prevention of Infections in Cirrhosis – Seminars in Liver Disease

 


RCT | Dupilumab in adults and adolescents with eosinophilic esophagitis

11 Jan, 2023 | 14:27h | UTC

Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Weekly Dupilumab Beneficial in Eosinophilic Esophagitis – HealthDay

 


M-A | Dietary interventions for the treatment of inflammatory bowel diseases

11 Jan, 2023 | 13:54h | UTC

Dietary interventions for the treatment of inflammatory bowel diseases: an updated systematic review and meta-analysis – Clinical Gastroenterology and Hepatology

 


RCT | The addition of Olanzapine to a triple antiemetic regimen effectively prevents nausea and vomiting during highly emetogenic chemotherapy.

16 Dec, 2022 | 13:32h | UTC

A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study) – eClinicalMedicine

Related:

RCT: Olanzapine may improve the control of vomiting in the delayed phase in children receiving highly emetogenic chemotherapy.

Randomized, open-label trial: Olanzapine seems effective for the prevention of vomiting in children and adolescents receiving highly emetogenic chemotherapy

Randomized Trial: Olanzapine Plus Standard Antiemetic Therapy for the Prevention of Chemotherapy-induced Nausea and Vomiting

 


Phase 1b/2a Study | Safety, pharmacokinetics, and pharmacodynamics of Pegozafermin in patients with non-alcoholic steatohepatitis.

16 Dec, 2022 | 13:29h | UTC

Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Polled analysis of RCTs | Linaclotide reduced response time for irritable bowel syndrome with constipation symptoms.

16 Dec, 2022 | 13:17h | UTC

Linaclotide Reduced Response Time for Irritable Bowel Syndrome With Constipation Symptoms: Analysis of 4 Randomized Controlled Trials – The American Journal of Gastroenterology

 


RCT | Hypophosphataemia following ferric derisomaltose vs. ferric carboxymaltose in patients with iron deficiency anemia due to IBD.

16 Dec, 2022 | 13:15h | UTC

Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial – Gut

 


A comprehensive systematic review of colorectal cancer screening clinical practices guidelines and consensus statements.

16 Dec, 2022 | 13:09h | UTC

A comprehensive systematic review of colorectal cancer screening clinical practices guidelines and consensus statements – British Journal of Cancer

 


SR | Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins.

14 Dec, 2022 | 14:51h | UTC

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins – Cochrane Library

 


Stay Updated in Your Specialty

No spam, just news.